West Pharmaceutical Services (WST) Non-Current Debt (2009 - 2026)

West Pharmaceutical Services' Non-Current Debt history runs 18 years deep, the most recent figure standing at $202.8 million for Q1 2026.

• In Q1 2026, Non-Current Debt changed 0.1% year-over-year to $202.8 million; the TTM figure through Mar 2026 stood at $202.8 million (changed 0.1% YoY), while the FY2025 annual figure was $202.8 million, changed 0.1% from the prior year.
• Non-Current Debt came in at $202.8 million for Q1 2026 at West Pharmaceutical Services, roughly flat from $202.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $208.3 million in Q1 2022 to a low of $72.8 million in Q4 2023.
• A 5-year average of $178.3 million and a median of $202.7 million in 2025 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt slumped 64.78% in 2023 and jumped 178.3% in 2024, its largest moves.
• West Pharmaceutical Services' Non-Current Debt stood at $206.7 million in 2022, then plunged by 64.78% to $72.8 million in 2023, then surged by 178.3% to $202.6 million in 2024, then advanced by 0.1% to $202.8 million in 2025, then changed by 0.0% to $202.8 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $202.8 million, $202.8 million, and $202.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison